There is early progress in the development of non-PD-1 checkpoint inhibitors such as anti-LAG3, anti-TIGIT and anti TIM3 therapies in oesophageal cancer, and these are currently being investigated alone or in combination with anti-PD-1 (Table 2). This evidence concerns the gene TIGIT and carcinoma of esophagus.